| abstract |
Compounds of formula (I), wherein R?1 and R2¿ each independently represent: hydrogen, C¿1-8?alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R?3R4NC¿2-6alkyl (where R?3 and R4¿ independently represent H or C¿1-4?alkyl) or NR?1R2¿ represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR5, (where R5 is H, C¿1-4?alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S or NR?6¿ (where R6 is hydrogen, C¿1-4?alkyl or arylC1-4alkyl); Y represents O, S, C=O or a bond; n is 2 to 5; m is 1 to 5 (providing that when m is 1, Y represents a bond); and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk?1)¿pA(Alk2)q- where Ph isoptionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent C¿1-4?alkyl which may be straight or branched and p and q are independently 0 or 1, provided that the length of -(Alk?1)¿pA(Alk2)q- does not exceed 5 atoms, or Ar is an optionally substitued tricyclic heteroaryl group (a) in which Y?1 is Y2(CH¿2)r where r is 0 or 1 and Y2 is O, S or NR7 where R7 is hydrogen or C¿1-4?alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; and pharmaceutically acceptable salts thereof are useful as atherapeutic agents, e.g. for the treatment of ischaemic stroke. |